CLINICAL EVALUATION OF SIDDHA MEDICINE MURUNGAI NEI FOR AAN MALADU (MALE INFERTILITY DUE TO OLIGOSPERMIA)

PHASE II NON-RANDOMIZED OPEN CLINICAL EVALUATION OF SIDDHA MEDICINE MURUNGAI NEI FOR AAN MALADU (MALE INFERTILITY DUE TO OLIGOSPERMIA)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/11/047534

Enrollment

Registered

2022-11-22

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N461- Oligospermia

Interventions

Intervention1: MURUNGAI NEI: It is an oral drug in Nei form. 6 grams, twice a day, after food Control Intervention1: Not Applicable: Not Applicable Control Intervention2: Not Applicable: Not Applicabl

Eligibility

Inclusion criteria

Inclusion criteria: 1.Marital status-more than 1 year. 2.Oligospermia (Sperm count 3.Asthenozoospermia (Motility less than 40%) 4.Oligoasthenozoospermia.

Exclusion criteria

Exclusion criteria: 1.Azoospermia. 2.Teratospermia. 3.Oligo-astheno-teratozoospermia 4.Erectile Dysfunction. 5.Hydrocele. 6.Varicocele. 7.Diabetes Mellitus. 8.Hypertension. 9.Cardia Diseases.

Design outcomes

Primary

Measure	Time frame
Increased sperm count and increased motility function is assessed by semen analysis. Any one or more among the above in a period of 48 days or more during the study will be considered as primary outcome.Timepoint: Increased sperm count and increased motility function is assessed by semen analysis. Any one or more among the above in a period of 48 days or more during the study will be considered as primary outcome.	—

Measure

Time frame

Increased sperm count and increased motility function is assessed by semen analysis. Any one or more among the above in a period of 48 days or more during the study will be considered as primary outcome.Timepoint: Increased sperm count and increased motility function is assessed by semen analysis. Any one or more among the above in a period of 48 days or more during the study will be considered as primary outcome.

—

Secondary

Measure	Time frame
Safety and Efficacy of the drug will be assessed during the course of the study.Timepoint: Safety and Efficacy will be assessed in a time period of 48 days.	—

Countries

India

Contacts

Public ContactDr Anu A

Government Siddha Medical College Chennai

mmsankar2000@gmail.com08220204424

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026